Progression-free survival as an end-point in clinical trials of biotherapeutic agents

European Journal of Cancer, Supplement

Volumn 5, Issue 9, 2007, Pages 23-28

  Bergmann, Lothar ^a   Hirschfeld, Steven ^b   Morris, Charles ^c   Palmeri, Sergio ^d   Stone, Andrew ^c  

^a GOETHE UNIVERSITY   (Germany)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anticancer agents; Biologics; Drug approval; Drug registration; End point; Progression free survival; Surrogate; Targeted agents

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; LAPATINIB; PACLITAXEL; PANITUMUMAB; PLACEBO; SORAFENIB; UNCLASSIFIED DRUG; VECTIBIX;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE COURSE; DRUG INDUSTRY; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 36549046994     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2007.09.002     Document Type: Article

References (18)

1. Committee for Medicinal Products for Human Use (CHMP). CPMP/EWP/205/95/Rev.3. Guideline on the Evaluation of Anticancer Medicinal Products in Man. 14 Dec 2005. London, England. [accessed 25.03.2007].
2. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007 May. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. [accessed 14.05.2007].
3. National Cancer Institute, U.S. Department of Health and Human Services. Dictionary of Cancer Terms. [accessed 24.03.2007].
4. .
5. Luri A.J., Djulbegovic B., Nebeker J.R., Angelotta C., Gordon L.I., Raisch D.W., et al. Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise?. J Clin Oncol, ASCO Proc 24 (2006) 6026
6. .
7. Palmeri S, Bergh J, Bergmann L, Hansen SW, Moraleda JM, Marty M, et al. The European medicines Agency/EMEA) guidelines on oncology drug development. JCO 2007, 25 [abstr 6636].
8. Panageas K.S., Ben-Porat L., Dickler M.N., Chapman P.B., and Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99 (2007) 428-432
9. Stone A., Wheeler C., and Barge A. Improving the design of phase II trials of cytostatic anticancer agents. Contemp Clin Trials 28 (2007) 138-145
10. Eisenhauer E.A. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. Ann Oncol 9 (1998) 1047-1052
11. Sandler AB, Gray R, Perry MC, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. ASCO 2005 [abstract LBA4].
12. Escudier B., Eisen T., Stadler W.M., et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
13. Stone A., Wheeler C., and Barge A. Improving the design of phase II trials of cytostatic anticancer agents. Contemp Clin Trials 28 (2007) 138-145
14. Stone A., Wheeler C., Carroll K., and Barge A. Optimizing randomized phase II trials assessing tumor progression. Contemp Clin Trials 28 (2007) 146-152
15. Freidlin B., and Simon R. Evaluation of randomised discontinuation design. J Clin Oncol 23 (2005) 5094-5098
16. Whitehead J. The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. Stat Med 8 (1989) 1439-1454
17. Carroll K.J. Analysis of progression-free survival in oncology trials: Some common statistical issues. Pharmaceut Stat 6 (2007) 99-111
18. Stone A., Fernandes N., and Morris C. Myths in the assessment of progression. How frequently should we assess patients in clinical trials?. Proc Am Soc Clin Oncol (2007) 6521